Contact
Please use this form to send email to PR contact of this press release:
Targazyme, Inc. Receives FDA Clearance For a Phase 2 Study of Pediatric Cancer Patients Undergoing Stem Cell Transplantation For Treatment of Hematologic Malignancies
TO: